Media coverage about Phibro Animal Health (NASDAQ:PAHC) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Phibro Animal Health earned a coverage optimism score of 0.25 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.3874447342569 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Phibro Animal Health (NASDAQ PAHC) opened at $35.15 on Thursday. The stock has a market cap of $1,410.00, a PE ratio of 20.68, a P/E/G ratio of 4.12 and a beta of 1.27. The company has a current ratio of 3.26, a quick ratio of 1.85 and a debt-to-equity ratio of 1.91. Phibro Animal Health has a 52-week low of $26.10 and a 52-week high of $40.25.
Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.01. The business had revenue of $193.40 million for the quarter, compared to the consensus estimate of $189.89 million. Phibro Animal Health had a net margin of 8.22% and a return on equity of 39.76%. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.36 EPS. analysts forecast that Phibro Animal Health will post 1.57 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 27th. Shareholders of record on Wednesday, December 6th were issued a dividend of $0.10 per share. The ex-dividend date was Tuesday, December 5th. This represents a $0.40 annualized dividend and a yield of 1.14%. Phibro Animal Health’s dividend payout ratio is currently 23.53%.
PAHC has been the topic of a number of research reports. Zacks Investment Research raised shares of Phibro Animal Health from a “sell” rating to a “hold” rating in a research report on Monday. BidaskClub lowered shares of Phibro Animal Health from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. ValuEngine lowered shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $42.00 price target on shares of Phibro Animal Health in a report on Friday, November 10th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Phibro Animal Health has a consensus rating of “Hold” and a consensus target price of $38.25.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/11/phibro-animal-health-pahc-receives-daily-media-impact-score-of-0-25.html.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.